Pricing Log in Create free account

Aligos Therapeutics, Inc. (ALGS) vs Metagenomi Therapeutics, Inc. (MGX)

Aligos Therapeutics, Inc. and Metagenomi Therapeutics, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and Metagenomi Therapeutics, Inc. are of similar size ($28.2M and $27.6M). Aligos Therapeutics, Inc. grew revenue faster over the last twelve months: 1,171.6% against −59.8%. Aligos Therapeutics, Inc. has the higher net margin (−197.0% vs −689.2%) and the lower return on invested capital (−400.9% vs 0.00%). Across the 15 metrics below, Aligos Therapeutics, Inc. leads on 9 and Metagenomi Therapeutics, Inc. on 6.

Valuation

Metric ALGS MGX Biotechnology median
P/E n/m n/m 10.60
P/S 1.27 1.94 9.40
P/B 3.78 0.23 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.66 0.66
EV/Sales 0.37 (4.72) 9.02
Earnings yield (155.26%) (355.71%) (32.88%)
Free cash flow yield (160.62%) (325.47%) (23.13%)

Profitability

Metric ALGS MGX Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (215.55%) (741.58%) 0.00%
Net margin (197.01%) (689.20%) 0.00%
Free cash flow margin (203.21%) (632.67%) 0.00%
Return on equity (159.46%) (60.61%) (51.96%)
Return on assets (84.46%) (41.91%) (46.06%)
Return on invested capital (400.91%) 0.00% 0.00%

Growth

Metric ALGS MGX Biotechnology median
Revenue growth (TTM) 1,171.58% (59.84%) 6.76%
EPS growth (last fiscal year) 88.30% 0.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALGS MGX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.77 4.50 4.97
Net debt to EBITDA 0.87 1.71 1.01

Dividend

Metric ALGS MGX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALGS MGX Biotechnology median
Market cap 28.17m 27.60m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack